Chlamydia infection screening

Sexually transmitted diseases Main Page
Chlamydia infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
C. trachomatis
Other Chlamydiae
Differentiating Chlamydia Infection from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Other Imaging Findings
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Chlamydia infection screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Chlamydia infection screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Chlamydia infection screening
CDC on Chlamydia infection screening
Chlamydia infection screening in the news
Blogs on Chlamydia infection screening
Directions to Hospitals Treating Chlamydia infection
Risk calculators and risk factors for Chlamydia infection screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maliha Shakil, M.D. [2] Aysha Anwar, M.B.B.S[3]

Overview

According to the 2015 Sexually Transmitted Diseases Treatment Guidelines by the CDC, screening for chlamydia is recommended for sexually active women under 25 years, women over 25 who are at increased risk, all pregnant women under 25 years, pregnant women over 25 who are at increased risk, men who have sex with men, and individuals with HIV.

Screening

According to the 2015 Sexually Transmitted Diseases Treatment Guidelines by the CDC, screening for chlamydia is recommended. The guidelines are as follows:

Women

• Sexually active women under 25 years of age.
• Sexually active women aged 25 years and older if at increased risk.
• Retest approximately 3 months after treatment.

Pregnant Women

• All pregnant women under 25 years of age.
• Pregnant women, aged 25 and older if at increased risk.
• Retest during the 3rd trimester for women under 25 years of age or at risk.

Men

• Consider screening young men in high prevalence clinical settings or in populations with high burden of infection (e.g. MSM).
• At least annually for sexually active men who have sex with men (MSM) and then very 3 to 6 months if at increased risk.

Individuals with HIV

• For sexually active individuals, screen at first HIV evaluation, and at least annually thereafter.
• More frequent screening might be appropriate depending on individual risk behaviors and the local epidemiology.